The Supreme Court has instructed Zydus Lifesciences to approach the Delhi High Court. Zydus is seeking relief from an order ...

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1078 in its ...

In July, a single-judge bench of the Delhi High Court restrained Zydus Lifesciences from selling its breast cancer drug in ...

Zydus Lifesciences Q2 Results Live : Zydus Lifesciences declared their Q2 results on 12 Nov, 2024, reporting a notable ...

Zydus Lifesciences reported a 14% YoY net profit rise to Rs 911 crore for Q2FY25, driven by strong sales in India and the US.

Legal battle over Zydus' biosimilar breast cancer drug could impact generic competition, Supreme Court refuses interim relief ...

Zydus Lifesciences(NSEI:ZYDUSLIFE) has reported strong earnings growth, with a 65% increase, positioning it as a leader in the pharmaceutical sector. Recent developments include the World Health ...

Zydus Lifesciences Ltd shares closed at ₹ 948.95 on NSE on Tuesday following the Q2 results, 2.4% lower than the previous day ...

Zydus had approached the Supreme Court challenging the Delhi High Court's order, which prevented the company from producing ...

Ahmedabad-based Zydus Lifesciences on Tuesday reported a 13.8 per cent year-on-year (Y-o-Y) increase in consolidated net ...

Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 1050 in its research report ...